- Home
- PROK vs OPRX Comparison
PROK vs OPRX Comparison
Compare PROK & OPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- OPRX
- Stock Information
- Founded
- PROK 2015
- OPRX 2006
- Country
- PROK United States
- OPRX United States
- Employees
- PROK N/A
- OPRX N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- OPRX Business Services
- Sector
- PROK Health Care
- OPRX Consumer Discretionary
- Exchange
- PROK Nasdaq
- OPRX Nasdaq
- Market Cap
- PROK 334.8M
- OPRX 380.6M
- IPO Year
- PROK N/A
- OPRX N/A
- Fundamental
- Price
- PROK $3.11
- OPRX $18.19
- Analyst Decision
- PROK Buy
- OPRX Buy
- Analyst Count
- PROK 5
- OPRX 8
- Target Price
- PROK $6.25
- OPRX $11.81
- AVG Volume (30 Days)
- PROK 2.5M
- OPRX 373.4K
- Earning Date
- PROK 11-11-2025
- OPRX 11-12-2025
- Dividend Yield
- PROK N/A
- OPRX N/A
- EPS Growth
- PROK N/A
- OPRX N/A
- EPS
- PROK N/A
- OPRX N/A
- Revenue
- PROK $527,000.00
- OPRX $104,748,000.00
- Revenue This Year
- PROK $338.06
- OPRX $17.92
- Revenue Next Year
- PROK N/A
- OPRX $10.91
- P/E Ratio
- PROK N/A
- OPRX N/A
- Revenue Growth
- PROK N/A
- OPRX 25.89
- 52 Week Low
- PROK $0.46
- OPRX $3.78
- 52 Week High
- PROK $7.13
- OPRX $20.70
- Technical
- Relative Strength Index (RSI)
- PROK 54.93
- OPRX 49.17
- Support Level
- PROK $2.34
- OPRX $17.45
- Resistance Level
- PROK $3.02
- OPRX $18.93
- Average True Range (ATR)
- PROK 0.17
- OPRX 1.14
- MACD
- PROK 0.03
- OPRX -0.24
- Stochastic Oscillator
- PROK 65.59
- OPRX 21.08
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.